| Rx0000260 |
Galderma Laboratories |
06/30/2019 |
00299590645 |
Epiduo?Forte Gel 0.1% / 2.5% Pump 45GM (Adapalene and Benzoyl Peroxide) 3 mg/g, 25 mg/g |
04/05/2019 |
25.90 |
554.25 |
12/23/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2019 |
00299598030 |
Mirvaso? Topical Gel 0.33% 30GM (Brimonidine) 5 mg/g |
04/05/2019 |
23.45 |
501.15 |
03/25/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2019 |
00299598035 |
Mirvaso? Topical Gel 0.33% 30GM PUMP (Brimonidine) 5 mg/g |
04/05/2019 |
23.45 |
501.15 |
03/25/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug developed by Galderma |
| Rx0000260 |
Galderma Laboratories |
06/30/2019 |
00299382230 |
Oracea? Capsules 40MG (Doxycycline, USP) 40 mg/1 |
04/05/2019 |
34.55 |
738.95 |
12/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug purchased by Galderma more than five years ago |
| Rx0000034 |
Genentech USA |
09/30/2019 |
50242013601 |
Actemra 200mg (10mL) |
07/01/2019 |
27.30 |
1119.33 |
None |
Single Source Drug |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=315, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=323 |
Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. |
| Rx0000034 |
Genentech USA |
09/30/2019 |
50242013701 |
Actemra 400 mg (20mL) |
07/01/2019 |
54.60 |
2238.65 |
None |
Single Source Drug |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=316, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=324 |
Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. |
| Rx0000034 |
Genentech USA |
09/30/2019 |
50242013501 |
Actemra 80 mg (4mL) |
07/01/2019 |
10.92 |
447.73 |
None |
Single Source Drug |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=314, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=322 |
Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. |
| Rx0000034 |
Genentech USA |
09/30/2019 |
50242013801 |
Actemra SC 162 mg (0.9 mL) |
07/01/2019 |
29.54 |
1014.26 |
None |
Single Source Drug |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=317, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=325 |
Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. |
| Rx0000034 |
Genentech USA |
09/30/2019 |
50242007001 |
Gazyva 1,000 mg (40mL) |
07/01/2019 |
96.81 |
6551.00 |
None |
Single Source Drug |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=328 |
Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. |
| Rx0000034 |
Genentech USA |
09/30/2019 |
50242012001 |
TNKase 50 mg 1VILY US |
07/01/2019 |
175.86 |
6037.73 |
None |
Single Source Drug |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=321, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=329 |
Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958200201 |
DESCOVY (emtricitabine tenofovir alafenamide) tablets |
03/16/2019 |
82.11 |
1757.90 |
08/15/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958190101 |
GENVOYA (elvitegravir cobicistat emtricitabine tenofovir alafenamide) tablets |
03/16/2019 |
144.34 |
3089.99 |
10/04/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958050101 |
HEPSERA (adefovir dipivoxil) tablets |
03/16/2019 |
69.34 |
1484.35 |
07/23/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958210101 |
ODEFSEY (emtricitabine rilprivirine tenofovir alafenamide) tablets |
03/16/2019 |
131.36 |
2812.13 |
08/15/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958070301 |
TRUVADA (emtricitabine 100mg/tenofovir disoproxil fumarate 150mg) tablets |
03/16/2019 |
82.11 |
1757.90 |
09/09/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958070401 |
TRUVADA (emtricitabine 133mg/tenofovir disoproxil fumarate 200mg) tablets |
03/16/2019 |
82.11 |
1757.90 |
09/09/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958070501 |
TRUVADA (emtricitabine 167 mg/tenofovir disoproxil fumarate 250mg) tablets |
03/16/2019 |
82.11 |
1757.90 |
09/09/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958070101 |
TRUVADA (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets |
03/16/2019 |
82.11 |
1757.90 |
01/13/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958140101 |
TYBOST (cobicistat) tablets |
03/16/2019 |
10.77 |
230.66 |
09/03/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958040401 |
VIREAD (tenofovir disoproxil fumarate) 150mg tablets |
03/16/2019 |
51.78 |
1108.50 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958040501 |
VIREAD (tenofovir disoproxil fumarate) 200mg tablets |
03/16/2019 |
51.78 |
1108.50 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958040601 |
VIREAD (tenofovir disoproxil fumarate) 250mg tablets |
03/16/2019 |
51.78 |
1108.50 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958040101 |
VIREAD (tenofovir disoproxil fumarate) 300mg tablets |
03/16/2019 |
55.87 |
1196.09 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2019 |
61958040301 |
VIREAD (tenofovir disoproxil fumarate) powder |
03/16/2019 |
30.46 |
652.18 |
07/25/2018 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000088 |
Gilead Sciences, LLC |
03/31/2019 |
15584010101 |
ATRIPLA (efavirenz emtricitabine tenofovir disoproxil fumarate) tablets |
03/16/2019 |
133.48 |
2857.55 |
04/28/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173086910 |
ANORO ELLIPT AER 62.5-25 |
01/01/2019 |
11.93 |
409.59 |
11/29/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173087410 |
ARNUITY ELPT INH 100MCG |
01/01/2019 |
5.06 |
173.56 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173087414 |
ARNUITY ELPT INH 100MCG |
01/01/2019 |
2.36 |
80.99 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173087610 |
ARNUITY ELPT INH 200MCG |
01/01/2019 |
6.77 |
232.36 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173087614 |
ARNUITY ELPT INH 200MCG |
01/01/2019 |
3.16 |
108.44 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173071204 |
AVODART CAP 0.5MG |
01/01/2019 |
17.31 |
594.32 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173071215 |
AVODART CAP 0.5MG |
01/01/2019 |
5.77 |
198.14 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173085910 |
BREO ELLIPTA INH 100-25 |
01/01/2019 |
10.23 |
351.27 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173085914 |
BREO ELLIPTA INH 100-25 |
01/01/2019 |
3.94 |
135.32 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173088210 |
BREO ELLIPTA INH 200-25 |
01/01/2019 |
10.23 |
351.27 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173088214 |
BREO ELLIPTA INH 200-25 |
01/01/2019 |
3.94 |
135.32 |
10/11/2030 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00007414120 |
COREG TAB 12.5MG |
01/01/2019 |
14.39 |
494.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00007414220 |
COREG TAB 25MG |
01/01/2019 |
14.39 |
494.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00007413920 |
COREG TAB 3.125MG |
01/01/2019 |
14.39 |
494.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00007414020 |
COREG TAB 6.25MG |
01/01/2019 |
14.39 |
494.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173060200 |
FLOVENT DISK AER 100MCG |
01/01/2019 |
3.17 |
108.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173060202 |
FLOVENT DISK AER 100MCG |
01/01/2019 |
5.45 |
187.18 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173060100 |
FLOVENT DISK AER 250MCG |
01/01/2019 |
4.25 |
145.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173060102 |
FLOVENT DISK AER 250MCG |
01/01/2019 |
7.30 |
250.59 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173060002 |
FLOVENT DISK AER 50MCG |
01/01/2019 |
5.17 |
177.49 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173071920 |
FLOVENT HFA AER 110MCG |
01/01/2019 |
7.30 |
250.59 |
08/26/2026 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173072020 |
FLOVENT HFA AER 220MCG |
01/01/2019 |
11.34 |
389.23 |
08/26/2026 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173071820 |
FLOVENT HFA AER 44MCG |
01/01/2019 |
5.45 |
187.18 |
08/26/2026 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173073900 |
IMITREX INJ 4MG/0.5 |
01/01/2019 |
11.89 |
408.29 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173073902 |
IMITREX INJ 4MG/0.5 |
01/01/2019 |
11.26 |
386.69 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173044902 |
IMITREX INJ 6MG/0.5 |
01/01/2019 |
27.73 |
952.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173047800 |
IMITREX INJ 6MG/0.5 |
01/01/2019 |
11.26 |
386.69 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173047900 |
IMITREX INJ 6MG/0.5 |
01/01/2019 |
11.89 |
408.29 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173052300 |
IMITREX SPR 20MG/ACT |
01/01/2019 |
14.25 |
489.13 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173052400 |
IMITREX SPR 5MG/ACT |
01/01/2019 |
14.25 |
489.13 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173073701 |
IMITREX TAB 100MG |
01/01/2019 |
17.12 |
587.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173073601 |
IMITREX TAB 50MG |
01/01/2019 |
17.12 |
587.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173080913 |
JALYN CAP |
01/01/2019 |
5.77 |
198.14 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173080959 |
JALYN CAP |
01/01/2019 |
17.31 |
594.32 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173052700 |
LAMICTAL CHW 25MG |
01/01/2019 |
38.64 |
1326.68 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173052600 |
LAMICTAL CHW 5MG |
01/01/2019 |
35.99 |
1235.82 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173063310 |
LAMICTAL KIT START 35 |
01/01/2019 |
13.02 |
447.04 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173059402 |
LAMICTAL KIT START 49 |
01/01/2019 |
18.60 |
638.54 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173081728 |
LAMICTAL KIT START 98 |
01/01/2019 |
37.20 |
1277.07 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173077800 |
LAMICTAL ODT KIT |
01/01/2019 |
15.65 |
537.16 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173077900 |
LAMICTAL ODT KIT |
01/01/2019 |
10.95 |
376.03 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173077602 |
LAMICTAL ODT TAB 100MG |
01/01/2019 |
10.72 |
368.14 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173077702 |
LAMICTAL ODT TAB 200MG |
01/01/2019 |
12.80 |
439.31 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173077202 |
LAMICTAL ODT TAB 25MG |
01/01/2019 |
9.39 |
322.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173077402 |
LAMICTAL ODT TAB 50MG |
01/01/2019 |
10.06 |
345.26 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173064255 |
LAMICTAL TAB 100MG |
01/01/2019 |
42.49 |
1458.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173064360 |
LAMICTAL TAB 150MG |
01/01/2019 |
27.94 |
959.38 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173064460 |
LAMICTAL TAB 200MG |
01/01/2019 |
30.42 |
1044.38 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173063302 |
LAMICTAL TAB 25MG |
01/01/2019 |
37.20 |
1277.19 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173075800 |
LAMICTAL XR KIT |
01/01/2019 |
11.45 |
393.16 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173075900 |
LAMICTAL XR KIT |
01/01/2019 |
32.71 |
1123.13 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173076000 |
LAMICTAL XR KIT |
01/01/2019 |
16.36 |
561.59 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173075600 |
LAMICTAL XR TAB 100MG |
01/01/2019 |
21.03 |
721.88 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173075700 |
LAMICTAL XR TAB 200MG |
01/01/2019 |
22.42 |
769.80 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173078100 |
LAMICTAL XR TAB 250MG |
01/01/2019 |
30.58 |
1049.76 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173075400 |
LAMICTAL XR TAB 25MG |
01/01/2019 |
9.82 |
337.00 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173076100 |
LAMICTAL XR TAB 300MG |
01/01/2019 |
33.63 |
1154.72 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173075500 |
LAMICTAL XR TAB 50MG |
01/01/2019 |
19.63 |
673.92 |
06/14/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173066518 |
MEPRON SUS |
01/01/2019 |
43.86 |
1506.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173052000 |
SEREVENT DIS AER 50MCG |
01/01/2019 |
6.66 |
228.78 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173052100 |
SEREVENT DIS AER 50MCG |
01/01/2019 |
11.29 |
387.53 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173056504 |
VALTREX TAB 1GM |
01/01/2019 |
18.79 |
645.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173056510 |
VALTREX TAB 1GM |
01/01/2019 |
56.37 |
1935.31 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173093308 |
VALTREX TAB 500MG |
01/01/2019 |
10.74 |
368.62 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173093310 |
VALTREX TAB 500MG |
01/01/2019 |
32.21 |
1105.77 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173093356 |
VALTREX TAB 500MG |
01/01/2019 |
36.58 |
1256.07 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173094755 |
WELLBUTRIN TAB 100MG SR |
01/01/2019 |
12.10 |
415.46 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173013555 |
WELLBUTRIN TAB 150MG SR |
01/01/2019 |
12.97 |
445.27 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2019 |
00173072200 |
WELLBUTRIN TAB 200MG SR |
01/01/2019 |
24.08 |
826.85 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |